CytRx Corp. (CYTR) Begins Phase 1b Clinical Trial for Aldoxorubicin in Tumor Patients
CytRx is a biopharmaceutical research and development company specializing in oncology. The company's oncology drug pipeline includes three programs in clinical development for cancer indications: aldoxorubicin, tamibarotene, and bafetinib. The company today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and evaluate the preliminary efficacy of its aldoxorubicin drug (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors that have failed to be helped by other therapies. Aldoxorubicin is a tumor-targeting conjugate of doxorubicin. Recent animal trials using this drug combination have showed favorable…